Assembly Biosciences Stock Performance
| ASMB Stock | USD 31.74 0.18 0.57% |
On a scale of 0 to 100, Assembly Biosciences holds a performance score of 6. The firm shows a Beta (market volatility) of 1.0, which signifies a somewhat significant risk relative to the market. Assembly Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Assembly Biosciences is expected to follow. Please check Assembly Biosciences' semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Assembly Biosciences' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Assembly Biosciences are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Assembly Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 19.8 M | |
| Total Cashflows From Investing Activities | 40.2 M |
Assembly Biosciences Relative Risk vs. Return Landscape
If you would invest 2,766 in Assembly Biosciences on October 12, 2025 and sell it today you would earn a total of 408.00 from holding Assembly Biosciences or generate 14.75% return on investment over 90 days. Assembly Biosciences is currently generating 0.2882% in daily expected returns and assumes 3.6487% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Assembly, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Assembly Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assembly Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Assembly Biosciences, and traders can use it to determine the average amount a Assembly Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.079
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ASMB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Assembly Biosciences is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Assembly Biosciences by adding it to a well-diversified portfolio.
Assembly Biosciences Fundamentals Growth
Assembly Stock prices reflect investors' perceptions of the future prospects and financial health of Assembly Biosciences, and Assembly Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Assembly Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | 269.39 M | ||||
| Shares Outstanding | 15.82 M | ||||
| Price To Earning | (10.58) X | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 13.42 X | ||||
| Revenue | 28.52 M | ||||
| EBITDA | (45.29 M) | ||||
| Cash And Equivalents | 116.69 M | ||||
| Cash Per Share | 2.41 X | ||||
| Total Debt | 3.09 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 11.55 X | ||||
| Cash Flow From Operations | (51.12 M) | ||||
| Earnings Per Share | (4.60) X | ||||
| Total Asset | 119.17 M | ||||
| Retained Earnings | (825.92 M) | ||||
| Current Asset | 68.37 M | ||||
| Current Liabilities | 3.4 M | ||||
About Assembly Biosciences Performance
By analyzing Assembly Biosciences' fundamental ratios, stakeholders can gain valuable insights into Assembly Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Assembly Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Assembly Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people.Things to note about Assembly Biosciences performance evaluation
Checking the ongoing alerts about Assembly Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Assembly Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Assembly Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 28.52 M. Net Loss for the year was (40.18 M) with loss before overhead, payroll, taxes, and interest of (24.65 M). | |
| Assembly Biosciences currently holds about 116.69 M in cash with (51.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.41. | |
| Roughly 56.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Anna Mowry of 160000 shares of Nautilus Biotechnology at 2.0 subject to Rule 16b-3 |
- Analyzing Assembly Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Assembly Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Assembly Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Assembly Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Assembly Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Assembly Biosciences' stock. These opinions can provide insight into Assembly Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |